On September 25, 2024, Evaxion Biotech A/S entered into a license agreement with MSD for two vaccine candidates, receiving an upfront payment of $3.2 million and potential future payments totaling $592 million per product. This agreement enhances their collaboration and has significant financial benefits for Evaxion.